Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan PK/PD in children with GERD
NCT06106022Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Maximum Drug Concentration at Steady-state at Day 14, Area Under the Plasma Concentration-time Curve During the Dosing Interval at Steady State at Day 14 and 2 more. Started Nov 2023; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06106022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106022.